PharVision Advisers’s Cognizant CTSH Stock Holding History

PharVision Advisers’s Portfolio CTSH Stock Details CTSH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-4,280	Closed	-$287K	–	746
2025 Q3	$287K	Buy	+4,280	New	+$309K	0.16%	253
2025 Q2	–	Sell	-4,492	Closed	-$344K	–	300
2025 Q1	$344K	Buy	+4,492	New	+$366K	0.48%	70

Other funds holding CTSH

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Pzena Investment Management New York $30.8B AUM 11.29% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

PharVision Advisers's CTSH Position: Q4 2025 in Review

PharVision Advisers sold out of Cognizant (CTSH) in Q4 2025, closing a stake of 4,280 shares — an estimated $287K sold.

PharVision Advisers first reported a position in CTSH in Q1 2025 and held it in 2 quarters. The position peaked at $344K in Q1 2025. 1,056 funds tracked by Wall St. Rank hold CTSH as of Q4 2025.

PharVision Advisers reported no remaining Cognizant position as of Q4 2025 after selling out during the quarter.
PharVision Advisers sold 4,280 Cognizant shares in Q4 2025, an estimated $287K.
PharVision Advisers first reported a position in Cognizant in Q1 2025 and held it in 2 quarters.
PharVision Advisers's Cognizant position peaked at $344K in Q1 2025.
1,056 funds tracked by Wall St. Rank held Cognizant as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.